Plus Three
Plus Three
Jul 15, 2021
#39 - Part One: Has Atai Life Sciences Taken the Psychedelic Throne From MAPS?
Play • 1 hr 2 min
Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences' recent IPO on Nasdaq. They also discuss and provide updates on Russell's previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits.


Co-hosts: Brian Normand, David Nickles, Russell Hausfeld, Sarvesh Ramprakash. Editor: Matt Payne

Episode links: 

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

No Direction Home by Norman Spinrad

Analyzing the Atai Life Sciences IPO | Business Trip podcast


If you like the show please support us on Patreon or make a tax-deductible donation

**Thank you to our Patreon podcast and video supporters: Reliable Spores, Houston Puck, Dave Hodges, Jon Hanna, James Hubbard, Lindsay Munson, Evan Freimuth, Abigail Bianchi, Meghan Kennedy, Dave Ayers, Darrell Duane, Tehseen Noorani, Tariqul Islam, Clifford Hudson, Daniel McQueen, Maryann Kehoe, Ben Yono, Nathan Espinosa, Annick McIntosh, Starbuck, Aaron Williams, Jenine Innes, Julia A, Jesse Liberty, Christian Dawley, Leon Boroditsky, Samy Tammam, Amanda Alexander, Jason Gross, Paige Hausfeld, John Bannon, Clifford Hudson, Sandra Dreisbach.

More episodes
Clear search
Close search
Google apps
Main menu